key: cord-0961151-203jfbp8 authors: Jie Chee, Ying; Jia Huey Ng, Shereen; Yeoh, Ester title: Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus date: 2020-04-24 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2020.108166 sha: eb747c96b754af26cd2bbab61a9cd61bbb767aac doc_id: 961151 cord_uid: 203jfbp8 nan There is scarce data on diabetic ketoacidosis (DKA) in Covid-19 infection. We report a case of DKA precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. A 37 year-old, previously healthy man presented with 1 week history of fever, vomiting, polydipsia and polyuria. On admission, his temperature was 38.5 o C. He was haemodynamically stable but mildly tachycardic. He did not display Kussmaul's breathing and did not require supplemental oxygen. His body mass index was 22.6 kg/m 2 with no evidence of insulin resistance. Given positive contact history, he was tested and confirmed to be infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Laboratory investigations (Table 1) were significant for hyperglycemia, high anion gap metabolic acidosis and ketonemia, confirming the diagnosis of DKA. In addition, the relationship between SARS-CoV-2 and the RAAS can complicate DKA management. Excessive fluid resuscitation may potentiate acute respiratory distress syndrome as angiotensin II increases pulmonary vascular permeability and worsens damage to lung parenchyma 5 . Furthermore, angiotensin II stimulates aldosterone secretion, potentiating the risk of hypokalemia, which may necessitate more potassium supplementation in order to continue intravenous insulin to suppress ketogenesis. In conclusion, it is possible that SARS-CoV-2 may aggravate pancreatic beta cell function and precipitate DKA. Further studies will help delineate the pathophysiology. We also highlight the pertinent clinical considerations in the concurrent management of two life-threatening conditions -DKA and Covid-19. Funding: None. Conflict of interest: None. Endocrine and metabolic link to coronavirus infection Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19 Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Advance online publication